Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,588.82
(
-0.54%
)
US TECH 100
23,594.80
(
-0.85%
)
Dow Jones
45,903.91
(
-0.69%
)
Brent Oil
104.85
(
-1.62%
)
Bitcoin
69,764.59
(
-2.07%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 05/04/2010 7:39:15 PM

Tuesday, May 04, 2010 7:39:15 PM

Post# of 257259
One bright spot for ITMN that hasn’t received any attention is that Roche recently licensed ITMN’s second-generation HCV protease inhibitor, which is in preclinical development and is as yet unnamed. A cynic might say that even this development is a negative, however. If Roche were happy with ITMN-191, why would they need another PI?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now